Oslo University Hospital, Department of Paediatrics, Oslo, Norway.
Respir Med. 2012 Feb;106(2):215-22. doi: 10.1016/j.rmed.2011.09.013. Epub 2011 Oct 19.
Limited knowledge exists about development of bronchial hyperresponsiveness (BHR) through adolescence. We aimed to assess changes in and risk factors for BHR in adolescence. From a Norwegian birth cohort 517 subjects underwent clinical examinations, structured interviews and methacholine challenges at age 10 and 16. BHR was divided into four categories: no BHR (cumulative methacholine dose required to reduce FEV(1) by 20% (PD(20)) >16 μmol), borderline BHR (PD(20) ≤16 and >8 μmol), mild to moderate BHR (PD(20) ≤8 and >1 μmol), and severe BHR (PD(20) ≤ 1 μmol). Logistic regression analysis was used to assess risk factors and possible confounders. The number of children with PD(20) ≤ 8 decreased from 172 (33%) to 79 (15%) from age 10-16 (p < 0.001). Most children (n = 295, 57%) remained in the same BHR (category) from age 10-16 (50% with no BHR), whereas the majority 182 (82%) of the 222 children who changed BHR category, had decreased severity at age 16. PD(20) ≤ 8 at age 10 was the major risk factor for PD(20) ≤ 8 6 years later (odds ratio 6.3), without significant confounding effect (>25% change) of gender, active rhinitis, active asthma, height, FEV(1)/FVC, or allergic sensitization. BHR decreased overall in severity through adolescence, was stable for the majority of children and only a minority (8%) had increased BHR from age 10 to 16. Mild to moderate and severe BHR at age 10 were major risk factors for PD(20) ≤ 8 at 16 years and not modified by asthma or body size.
关于支气管高反应性(BHR)在青春期的发展,目前的知识有限。我们旨在评估青少年时期 BHR 的变化及其危险因素。在一项挪威出生队列研究中,517 名受试者分别在 10 岁和 16 岁时接受了临床检查、结构化访谈和乙酰甲胆碱激发试验。BHR 分为四类:无 BHR(累积乙酰甲胆碱剂量使 FEV1 降低 20%所需的剂量(PD20)>16μmol)、边缘性 BHR(PD20≤16μmol 且>8μmol)、轻度至中度 BHR(PD20≤8μmol 且>1μmol)和重度 BHR(PD20≤1μmol)。采用逻辑回归分析评估危险因素和可能的混杂因素。从 10 岁到 16 岁,PD20≤8 的儿童数量从 172 人(33%)减少到 79 人(15%)(p<0.001)。大多数儿童(n=295,57%)在 10-16 岁时保持相同的 BHR(类别)(50%无 BHR),而在 222 名 BHR 类别发生变化的儿童中,大多数(82%)16 岁时 BHR 严重程度降低。10 岁时 PD20≤8 是 6 年后 PD20≤8 的主要危险因素(比值比 6.3),性别、活动性鼻炎、活动性哮喘、身高、FEV1/FVC 或过敏敏化无显著混杂效应(>25%变化)。通过青春期,BHR 的严重程度总体上有所下降,对于大多数儿童来说是稳定的,只有少数(8%)儿童从 10 岁到 16 岁 BHR 增加。10 岁时的轻度至中度和重度 BHR 是 16 岁时 PD20≤8 的主要危险因素,且不受哮喘或体型的影响。